Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit
Danish Biotech Banks $40m milestone payment
Executive Summary
The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.
You may also be interested in...
Anti-CD20 Bispecifics Could Find Niche In First-Line Lymphoma
Roche presented data at ASCO on its two CD20-targeting bispecific antibodies, showing high response rates in heavily pretreated non-Hodgkin lymphoma patients.
Genmab Commercial Expansion Opens The Door To New Types Of Deals
The company's CEO talked to Scrip about the expected US launch of tisotumab vedotin likely later in 2021 and the company's partnering strategy going forward.
AstraZeneca Cancer Pipeline Boost With AKT And SERD Successes
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.